Abstract 5929
Background
Data for metastatic soft tissue sarcoma (STS) is sparse from developing countries. Pazopanib has demonstrated promising activity in the management of this disease. This study was carried out in the dedicated sarcoma medical oncology clinic in a tertiary referral center of Western India.
Methods
This is a retrospective analysis of prospective database from adult sarcoma medical oncology clinic at Tata Memorial Center, Mumbai from January 2035 to December 2018. The patients were provided holistic care through involvement of palliative care team, government fundings, local NGOs and sarcoma support groups. All statistical calculations were done using SPSS version 20.
Results
A total of 314 patients diagnosed with metastatic STS were registered in the dedicated medical oncology sarcoma clinic, 72% were males and median age 46 (16-79) years. Out of 314 patients, 60 (19%) patients received Pazopanib at some point of time during their treatment. Most common histology was synovial sarcoma (28%), leiomyosarcoma (26%), unspecified high grade spindle cell sarcoma (19%) and alveolar soft part sarcoma (12%). The median follow up duration was 18 (4-41) months. Median lines of prior therapy were 2 (0-2). Among 42 evaluable patients, there were 24% partial responses, 48% stable disease and 28% progressive disease. Median progression free survival was 5 (95% CI 3-7.3) months and median overall survival was 11 (95% CI 6.8-16.2) months. Important adverse events (>grade 1) included hand foot syndrome (10%), diarrhea (10%), hypothyroidism (10%), fatigue (8%) and hyperbilirubinemia/transaminitis (8%). Notably 50% patients required dose reduction and median dose was 600(200-800) mg daily.
Conclusions
Pazopanib was found to be a feasible treatment option for metastatic STS in India with internationally comparable outcomes. Median tolerated dose was lower than the standard 800 mg dose. Outcomes could be improved due to dedicated clinic with availability of targeted therapy with government help and local NGOs. This model of providing holistic care can be replicated in rare tumors in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract